Skip to main content
TipRanks
Go Ultimate75% OFF

MacroGenics (M55) Q4 2024 Earnings Report

5 Followers

DE:M55 Q4 2024 EPS Results

Actual EPS
-EUR 0.22
Consensus EPS
-EUR 0.25
Beat/Miss
Beat by +EUR 0.04
One Year Ago EPS
-EUR 0.67

DE:M55 Q4 2024 Revenue Results

Actual Revenue
EUR 17.56M
Expected Revenue
EUR 32.40M
Beat/Miss
Missed by -EUR 14.84M
YoY Revenue Growth
+80.53%

Earnings Announcement Details

Quarter
Q4 2024
Date
03/20/2025
Time
After Close
Conference Call
Thursday, March 20, 2025
DE:M55 Upcoming Earnings

MacroGenics's next earnings date is estimated for February 25, 2027, based on past reporting schedules.

Q4 2024 Earnings Call Audio

DE:M55 Q4 2024 Earnings Call
0:00 / 0:00

Q4 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q4 2024 Earnings Call Summary

Q4 2024
Earnings Call Date:Mar 20, 2025|% Change Since:-2.89%|
Earnings Call Sentiment|Neutral

MacroGenics achieved significant clinical and financial milestones in 2024, marked by a substantial increase in revenues and strong progress in clinical trials. However, increased net losses and operating expenses, along with the discontinuation of vobra duo, present challenges. The company remains financially stable with a solid cash position and is poised for future growth.

Company Guidance

In the conference call, MacroGenics provided guidance and updates on their financial and clinical developments for the year 2024 while highlighting expectations for 2025. The company reported a total revenue of $150 million for 2024, a significant increase from $58.7 million in 2023, largely due to milestone achievements under the Incyte License Agreement. Research and development expenses rose to $177.2 million, up from $166.6 million in the previous year, reflecting increased costs related to their ADC pipeline and clinical trials. Cash, cash equivalents, and marketable securities totaled $201.7 million at the end of 2024, ensuring a cash runway into the second half of 2026. Clinically, MacroGenics provided updates on their investigational therapies, including the completion of enrollment in the 150-patient LORIKEET Phase 2 trial for lorigerlimab and plans to initiate the LINNET Phase 2 study in mid-2025. Additionally, three ADC molecules are in various stages of development, with MGC026 and MGC028 in clinical trials and MGC030 in preclinical studies. The company is also advancing MGD024, a bi-specific DART molecule, with ongoing Phase 1 studies.

  • Significant Revenue GrowthMacroGenics reported a total revenue of $150 million for the year ended December 31, 2024, compared to $58.7 million in 2023, primarily due to milestones achieved under the Incyte License Agreement.
  • Clinical Milestones in 2024MacroGenics completed enrollment in the LORIKEET Phase 2 trial for lorigerlimab and initiated the LINNET Phase 2 study. The company also advanced its ADC portfolio with MGC026, MGC028, and MGC030.
  • Strong Financial PositionCash, cash equivalents, and marketable securities balance was $201.7 million as of December 31, 2024, with projections extending the cash runway into the second half of 2026.
  • Successful Asset SaleCompleted the sale of MARGENZA to TerSera Therapeutics, yielding a $36.3 million gain and providing non-dilutive capital.

DE:M55 Earnings History

DE:M55 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 25, 20272026 (Q4)-0.29--0.21――
Nov 04, 20262026 (Q3)-0.29-0.290.24-218.52% (-0.54)
Aug 13, 20262026 (Q2)-0.070.28-0.52154.39% (+0.80)
May 13, 20262026 (Q1)-0.52-0.53-0.5910.77% (+0.06)
Mar 09, 20262025 (Q4)-0.11-0.21-0.224.17% (+0.01)
Nov 12, 20252025 (Q3)-0.400.240.82-70.00% (-0.57)
Aug 14, 20252025 (Q2)-0.38-0.52-0.8135.96% (+0.29)
May 13, 20252025 (Q1)-0.66-0.59-0.7622.62% (+0.17)
Mar 20, 20252024 (Q4)-0.25-0.22-0.6767.57% (+0.45)
Nov 05, 20242024 (Q3)0.190.820.25221.43% (+0.56)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed